Minimal Change Disease

Minimal Change Disease (MCD) is the most common cause of nephrotic syndrome in children (80–90%) and an important cause in adults (10–15% of primary nephrotic syndrome). It is characterized by normal light microscopy, diffuse podocyte foot process effacement on electron microscopy, and absence of immune deposits on immunofluorescence. Despite its name, minimal change refers to light microscopy findings — electron microscopy reveals extensive podocyte injury. MCD typically responds dramatically to corticosteroids, but relapsing disease is common.

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Clinical Presentation
  5. Diagnosis and Biopsy Findings
  6. Treatment — Initial Corticosteroid Therapy
  7. Treatment — Frequent Relapsers and Steroid-Resistant Disease
  8. Secondary Causes of MCD
  9. MCD in Adults vs. Children
  10. Prognosis
  11. Key Research Papers
  12. Featured Videos

Overview

Minimal Change Disease (MCD) is a glomerulopathy causing nephrotic syndrome via diffuse podocyte foot process effacement without immune deposits. It is the most common cause of nephrotic syndrome in children (80–90% of pediatric nephrotic syndrome under age 10; decreasing proportion in adolescents and adults). In adults, MCD accounts for 10–15% of primary nephrotic syndrome.

The name is a misnomer — light microscopy appears normal, but electron microscopy reveals near-total podocyte foot process effacement across all glomeruli. The disease is immune-mediated, likely involving T-lymphocyte dysfunction producing a circulating permeability factor (not yet definitively identified) that injures podocytes.

Idiopathic MCD responds to corticosteroids in 90% of children and 75–80% of adults, but relapses are frequent. Long-term kidney prognosis is generally excellent if remission is maintained, unlike FSGS which MCD can sometimes be confused with or progress to.


Back to Table of Contents

Epidemiology

Peak incidence in children ages 2–8 years (boys > girls 2:1 under age 6; equal over age 6). Annual incidence: 1–3 cases per 100,000 children per year in Western countries; higher in South Asian children. In adults: peak ages 20–30 (idiopathic MCD) and then again over 60 (secondary MCD from nonsteroidal anti-inflammatory drugs (NSAIDs) or lymphoma).

MCD accounts for 90% of childhood nephrotic syndrome under age 6, and approximately 50% in ages 6–12. Overall excellent prognosis with the majority achieving long-term remission. Fewer than 1% progress to end-stage renal disease (ESRD) without a misdiagnosis — most such cases reflect underlying FSGS misread as MCD on an inadequate biopsy sample.


Back to Table of Contents

Pathophysiology

The precise mechanism remains unclear, but current evidence supports a T-lymphocyte mediated disorder:

Antibodies against nephrin: a 2024 multicentre study of 539 patients found antibodies against nephrin (a protein of the kidney's filtration slit) in 46 of 105 adults (44%) with MCD and 94 of 182 children (52%) with idiopathic nephrotic syndrome, rising to 69% and 90% in those with active disease who were not yet on immunosuppressive treatment; only 7 of 74 adults (9%) with primary FSGS had them. Antibody levels tracked disease activity, and immunising mice with nephrin produced a nephrotic syndrome resembling MCD (an animal result). These antibodies are the strongest candidate so far for the long-sought circulating factor in some patients.


Back to Table of Contents

Clinical Presentation

Nephrotic syndrome is the hallmark presentation:


Back to Table of Contents

Diagnosis and Biopsy Findings

In children ages 1–8 with classic nephrotic syndrome, empirical steroid therapy is appropriate without prior biopsy (presumptive MCD; over 90% respond). Biopsy indications in children: age <1 or >10 years, hematuria, hypertension, low C3, family history of renal disease, or steroid resistance at 4–8 weeks.

In adults: biopsy is always required before treatment to distinguish MCD from FSGS, membranous nephropathy, and secondary causes.

Biopsy findings:

Lab findings: heavy proteinuria on urine dipstick (3–4+) and 24-hour collection; hypoalbuminemia; hyperlipidemia; normal complement (C3, C4); normal anti-dsDNA, antineutrophil cytoplasmic antibody (ANCA), and anti-GBM. Hematuria is absent or minimal (microscopic hematuria in <25%; gross hematuria is atypical and raises the possibility of FSGS).


Back to Table of Contents

Treatment — Initial Corticosteroid Therapy

For idiopathic MCD, prednisone (or prednisolone) is first-line:

Supportive measures:


Back to Table of Contents

Treatment — Frequent Relapsers and Steroid-Resistant Disease

Frequently relapsing MCD (2 or more relapses in the first 6 months after remission of the first episode, or 3 or more in any 12 months, per the 2023 IPNA definitions) and steroid-dependent MCD (2 consecutive relapses during prednisone therapy or within 14 days of stopping it):

Steroid-resistant MCD — failure to achieve remission after 16 weeks of steroids: re-biopsy to exclude FSGS (sampling error — MCD and FSGS can co-exist, or an early FSGS lesion may have been missed on initial biopsy). It is then usually treated as FSGS (CNI plus steroids).


Back to Table of Contents

Secondary Causes of MCD

Secondary causes are part of the evaluation of MCD, especially in adults:

Evaluation includes complete blood count, computed tomography scan, and positron emission tomography (PET) scan if lymphoma is suspected, along with a thorough medication review.


Back to Table of Contents

MCD in Adults vs. Children

Adults with MCD differ from children in several important ways:

In a 2007 series of 95 adults with MCD at one US referral centre, more than a quarter were steroid resistant, 73% relapsed at least once and 28% relapsed frequently; acute kidney failure occurred in 24, who tended to be older and hypertensive, and 4 progressed to kidney failure — these 4 were less likely to have responded to steroids and more likely to show FSGS on repeat biopsy.

FSGS is more common than MCD in adults presenting with nephrotic syndrome, compared to children where MCD predominates — hence biopsy is crucial in adults to avoid treating FSGS as MCD.

Transition to adult nephrology care is an important consideration for pediatric patients who continue to have disease into adulthood.


Back to Table of Contents

Prognosis

Children: excellent prognosis. The majority achieve long-term remission after initial or subsequent corticosteroid courses; fewer than 1% develop chronic kidney disease or ESRD. Most children with frequently relapsing disease eventually achieve sustained remission by adolescence.

Adults: also generally good, but with a higher rate of CNI-dependence, more frequent relapses, and occasional progression to chronic kidney disease (CKD) — particularly if the underlying diagnosis is actually FSGS that was misclassified due to sampling error on biopsy.

Factors associated with a more complicated course include: age >10 at onset (adults), frequently relapsing disease, steroid dependence, and requirement for multiple immunosuppressive agents. With careful immunosuppressive management, long-term kidney function preservation is expected in true MCD. The distinction from FSGS remains the most clinically important prognostic determinant.


Back to Table of Contents

Key Research Papers

  1. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274. [Superseded by the 2021 and 2025 KDIGO guidelines below.] — Search PubMed
  2. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276. — doi:10.1016/j.kint.2021.05.021 · PubMed PMID: 34556256
  3. Kidney Disease: Improving Global Outcomes (KDIGO) Nephrotic Syndrome In Children Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Kidney Int. 2025;107(5S):S241–S289. — doi:10.1016/j.kint.2024.11.007 · PubMed PMID: 40254391
  4. Vivarelli M, et al. Minimal Change Disease. Clin J Am Soc Nephrol. 2017;12(2):332–345. — Search PubMed · doi:10.2215/CJN.05000516
  5. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629–639. — PubMed PMID: 12944064 · doi:10.1016/S0140-6736(03)14184-0
  6. Waldman M, et al. Adult minimal change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445–453. — PubMed PMID: 17699450 · doi:10.2215/CJN.03531006
  7. Ravani P, Rossi R, Bonanni A, et al. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol. 2015;26(9):2259–2266. — doi:10.1681/ASN.2014080799 · PubMed PMID: 25592855
  8. Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384(9950):1273–1281. — doi:10.1016/S0140-6736(14)60541-9 · PubMed PMID: 24965823
  9. Sinha A, Bagga A. Nephrotic syndrome. Indian J Pediatr. 2012;79(8):1045–1055. — Search PubMed · doi:10.1007/s12098-012-0776-y
  10. Trautmann A, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023;38(3):877–919. — PubMed PMID: 36269406 · doi:10.1007/s00467-022-05739-3
  11. Caridi G, Bertelli R, Scolari F, Sanna-Cherchi S, Di Duca M, Ghiggeri GM. Podocin mutations in sporadic focal-segmental glomerulosclerosis occurring in adulthood. Kidney Int. 2003;64(1):365. — doi:10.1046/j.1523-1755.2003.00084.x · PubMed PMID: 12787432
  12. Hinkes BG, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet. 2006;38(12):1397–1405. — Search PubMed · doi:10.1038/ng1918
  13. Hengel FE, Dehde S, Lassé M, et al. Autoantibodies Targeting Nephrin in Podocytopathies. N Engl J Med. 2024;391(5):422–433. — doi:10.1056/NEJMoa2314471 · PubMed PMID: 38804512

Back to Table of Contents

PubMed Topic Searches

  1. PubMed: Minimal change disease nephrotic syndrome children treatment
  2. PubMed: Minimal change disease adults corticosteroids outcomes
  3. PubMed: Minimal change disease rituximab randomized trial
  4. PubMed: Minimal change disease calcineurin inhibitor tacrolimus
  5. PubMed: Minimal change disease T-cell pathogenesis cytokines
  6. PubMed: Podocyte foot process effacement nephrotic syndrome
  7. PubMed: FSGS minimal change disease differential diagnosis biopsy

Back to Table of Contents

Connections